文献发表

BREAST CANCER RESEARCH AND TREATMENT

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China

PredicineCARE™ liquid biopsy assay was utilized to evaluate the correlation between genomic alterations and progression-free survival in patients with hormone-receptor positive metastatic breast cancer in the US and China

September 2021

了解更多信息

EUROPEAN UROLOGY

Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial

In a study of patients with mCRPC, the PredicineCARE™ and PredicineRNA liquid biopsy assays were utilized to identify alterations that may be associated with a poorer prognosis. The study also demonstrated that serial testing of cfDNA offers the unique opportunity to predict benefit to therapy prior to the onset of biochemical or radiographic changes.

September 2021

了解更多信息

FRONTIERS IN ONCOLOGY

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer

The PredicineCARE™ liquid biopsy assay was utilized to identify PTEN, RB1 and TP53 copy number losses in plasma samples from patients with metastatic prostate cancer. These findings have profound clinical implications for a patient’s prognosis, treatment selection, and understanding subsequent resistance.

 

August 2021

了解更多信息

JOURNAL OF UROLOGY

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

PredicineCARE™ was applied for ultra-deep targeted sequencing and somatic alteration identification in tumor DNA (tDNA), urinary tumor DNA (utDNA), and circulating tumor DNA (ctDNA) in a UBC patient cohort and concordance was evaluated. 

 

June 2021

了解更多信息

FORTUNE JOURNALS

Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients

Using PredicineATLAS™ to analyze somatic mutations and copy number changes in PI3K/AKT pathway, NOTCH signaling pathway, hedgehog signaling pathway and pathways involved in DNA damage repair might be potential mechanisms underlying TKI resistance.

May 2021

了解更多信息

CANCER MANAGEMENT AND RESEARCH

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing

Using PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.

April 2021

了解更多信息

JCO PRECISION ONCOLOGY

Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

PTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.

April 2021

了解更多信息

THE BREAST

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

Using PredicineCARE™ to analyze mutational landscape of 158 tumor related genes in HER2-positive breast cancer patients.

November 2020

了解更多信息

Blood

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Using PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification. 

November 2020

了解更多信息

European Urology

Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

The first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.

May 2020

了解更多信息

European Urology

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.

May 2020

了解更多信息

EBioMedicine

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.

April 2020

了解更多信息

CHINESE JOURNAL OF CANCER RESEARCH

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing

Using Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.

February 2020

了解更多信息

CRITICAL REVIEWS IN ONCOLOGY

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Validation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms. 

January  2020

了解更多信息

BREAST CANCER RESEARCH

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

The potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.

December  2019

了解更多信息

壁报展示

ASCO 2021 VIRTUAL

Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

•Predictive value of germline ATM mutations in mPDAC patients receiving PD-L1 + CTLA4 combo immunotherapies, demonstrating the value of the PredicineATLAS test in both blood TMB profiling and germline profiling to identify patient subgroups who may benefit from immunotherapy.

June  2021

了解更多信息

AACR 2021 VIRTUAL

Comparative analysis of cell free DNA with whole-exome sequencing (cfWES) and application to personalized minimal residual disease (MRD) monitoring

•Validation of Predicine’s tissue-agnostic MRD assay that detects cancer variants down to 0.005%.

April  2021

了解更多信息

AACR 2021 VIRTUAL

Blood-based genome-wide copy number analysis of 500 cancer patients

• Predicine’s LP-WGS assay for identification of segment-based CNVs and CNV abnormality in plasma samples from 500 cancer patients, including breast, prostate, pancreatic and lung cancers.

April  2021

了解更多信息

AACR 2021 VIRTUAL

Cell-free DNA based methylation profiling for early cancer detection with Predicine methylation assay

• Predicine’s enzyme-controlled methylation assay demonstrates dramatic improvement over WGBS in reducing DNA damage and GC bias as well as increasing NGS reads mapping rate and mapping quality score.

April  2021

了解更多信息

AACR 2021 VIRTUAL

Blood-based detection of copy number loss and its clinical implication in prostate cancer

• Validation of PredcineCARE™’s ability to detect gene copy number loss (PTEN) in low fraction of tumor contents in plasma of prostate cancer patients.

April  2021

了解更多信息

ASCO-GU 2021 VIRTUAL

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza)

• Simultaneous profiling of Androgen Receptor splicing variants, hotspot mutations and amplifications at both cfDNA and cfRNA levels

 

February 2021 

了解更多信息

ASCO-GU 2021 VIRTUAL

Superior molecular pathology of urothelial bladder cancer using urinary cell-free DNA

• Urine-based liquid biopsy treatment selection, disease monitoring, and early cancer detection in bladder cancer

 

 

February 2021 

了解更多信息

ASCO-GU 2021 VIRTUAL

Circulating tumor DNA analysis of genomic alterations in metastatic urothelial carcinoma from NCT03113266 study

• Blood TMB towards personalized anti-PD-1 immunotherapy (toripalimab) in metastatic urothelial carcinoma

 

 

February 2021 

了解更多信息

ASCO-GU 2021 VIRTUAL

Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts

• Blood-based detection of copy number variations (CNVs) in the PTEN-PI3K-AKT and AR pathway

• PTEN copy number loss

 

February 2021 

了解更多信息

ASCO-GI 2021 VIRTUAL

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

• PredicineATLAS™ to assess the predictive value of plasma TMB in mPDAC

 

 

January 2021 

了解更多信息

SABCS 2020 VIRTUAL

Germline Mutation Landscape in Chinese Breast Cancer Patients

• PredicineATLAS™ to assess germline mutations in breast cancer populations with different clinical features

• Large cohort study to support the development of precision oncology therapies for breast cancer patients

 

 

December 2020 

了解更多信息

SITC 2020 VIRTUAL

Development and validation of blood tumor mutational burden reference standards

• Calibration and validation of bTMB platforms to help harmonization between panels and laboratories thus improving the accuracy of testing to aid treatment decisions in oncology

• PredicineATLAS™ to assess bTMB

• Collaboration with AstraZeneca 

November 2020 

了解更多信息

ASCO 2020 Virtual

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC)

• ctDNA changes correlate with ORR in BTC patients treated with durvalumab + tremelimumab immunotherapy

• PredicineATLAS™ cfDNA

• Collaboration with AstraZeneca 

May  2020

了解更多信息

AACR - ADVANCES IN LIQUID BIOPSIES 2020

Simultaneous Multi-parametric Profiling of Cell-free RNA (cfRNA) and Cell-free Tumor DNA (ctDNA) in Advanced-stage Colorectal Cancer

• ctDNA and cfRNA profiling, TMB

• Matched plasma and tissue

• Collaboration with Merck KGaA and EMD Serono

January  2020

了解更多信息

AACR 2020 VIRTUAL

Development of cfDNA-based methylation assay for early cancer detection

• Methylation profiling in plasma cfDNA and urinary cfDNA

• PredicineMETHYLATION™ 

• Early cancer detection

June  2020

 

 

了解更多信息

AACR 2020 VIRTUAL

Urine-based molecular biomarker signatures for bladder cancer

• Urinary cfDNA

• TERT, FGFR3, PIK3CA, PIK3CB

• Bladder cancer

June  2020

 

 

了解更多信息

AACR 2020 VIRTUAL

Combined cell-free DNA and cell-free RNA NGS testing for cancer patient care

• Fusions and splice variants in cfRNA

• PredicineRNA™ 

• NSCLC and mCRPC

June  2020

 

 

了解更多信息

ASCO 2020 Virtual

Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China

• ctDNA profiling

• HR+ mBC

• PTEN, PIK3CA, TP53, FGFR1

May  2020

了解更多信息

ASCO-GU 2020

Biomarker Analysis (CTC and ctDNA/RNA) of GT0918 (Proxalutamide) New AR blocker in Phase I mCRPC Patients with Dose Escalation

• ctDNA profiling for AR mutation and amplification

• cfRNA profiling for AR-V7 splicing variants

• Therapy response and drug resistance

January 2020

了解更多信息

ASCO-GU 2019

Plasma-based exploratory biomarker analysis to evaluate GT0918 in a Phase 1/2 study in mCRPC patients

• PTEN-PI3K, AR, DDR pathway alterations

• Mono- vs. bi-allelic gene deletion in BRCA, PTEN

• cfRNA-based detection of fusions and splice variants

January 2019

了解更多信息

摘要发布

2019 SABCS

Characterization of metastatic breast cancer through a novel next generation sequencing platform for hypothesis generation on endocrine resistance

Lorenzo Gerratana, Qiang Zhang, Andrew A Davis, Ami N Shah, Jianjun Yu, Shidong Jia, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradisha, and Massimo Cristofanilli

December 2019

了解更多信息

2019 SABCS

Blood-based detection of PTEN loss and pathway alterations for personalized treatment of breast cancer

Pan Du, Eric Jia and Zhixin Zhao

December 2019

了解更多信息

2019 SABCS

Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA

Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli

December 2019

了解更多信息

2019 ASCO

Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee

June 2019

了解更多信息

2019 AACR

Combined immunohistochemistry and NGS-based patient profiling for predicting anti-PD-1/PD-L1 therapy response

Jianjun Yu, Jianguo Dong, Amy Wang, Joseph S. Krueger

April 2019

了解更多信息

2019 AACR

Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients

Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad

April 2019

了解更多信息

2019 AACR

Development and validation of PredicineATLAS, a 600-gene liquid biopsy panel for simultaneous detection of TMB and genomic alterations in immuno-oncology

Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du

April 2019

了解更多信息

2019 ASCO-GU

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer

Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu

February 2019

了解更多信息

2018 SABCS

Molecular characterization of circulating tumor DNA in Chinese metastatic breast cancer (mBC) patients

Yu J, Li H, Zhang S, Wang A, Zhao Z

December 2018

了解更多信息

联系我们

竭诚欢迎您前来洽谈业务合作!

请留下您的联系方式,我们会尽快与您沟通交流。